Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Omeros Corporation - Common Stock
(NQ:
OMER
)
18.61
+0.14 (+0.76%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Omeros Corporation - Common Stock
< Previous
1
2
3
4
5
Next >
Omeros Corporation Reports Second Quarter 2026 Financial Results
August 12, 2026
From
Omeros Corporation
Via
Business Wire
Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026
August 10, 2026
From
Omeros Corporation
Via
Business Wire
CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA®
August 03, 2026
From
Omeros Corporation
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
July 28, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER
July 21, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
July 14, 2026
From
Pomerantz LLP
Via
GlobeNewswire
OMER Investors Have Opportunity to Join Omeros Corporation Fraud Investigation with the Schall Law Firm
July 08, 2026
From
Schall Law
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
July 07, 2026
From
Pomerantz LLP
Via
GlobeNewswire
OMER Investors Have Opportunity to Join Omeros Corporation Fraud Investigation with the Schall Law Firm
July 06, 2026
From
The Schall Law Firm
Via
Business Wire
Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA
June 26, 2026
From
Omeros Corporation
Via
Business Wire
Omeros Announces Webcast Details for Annual Meeting of Shareholders
June 15, 2026
From
Omeros Corporation
Via
Business Wire
Omeros Corporation Reports First Quarter 2026 Financial Results
May 13, 2026
From
Omeros Corporation
Via
Business Wire
Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026
May 11, 2026
From
Omeros Corporation
Via
Business Wire
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer
April 20, 2026
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)
April 16, 2026
From
Omeros Corporation
Via
Business Wire
Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results
March 31, 2026
From
Omeros Corporation
Via
Business Wire
Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026
March 26, 2026
From
Omeros Corporation
Via
Business Wire
Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment
March 21, 2026
From
Omeros Corporation
Via
Business Wire
Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program
February 17, 2026
From
Omeros Corporation
Via
Business Wire
Omeros Announces First Commercial Sales of YARTEMLEA®
January 27, 2026
From
Omeros Corporation
Via
Business Wire
Omeros Announces New Date for YARTEMLEA® Approval Conference Call
December 26, 2025
From
Omeros Corporation
Via
Business Wire
FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA
December 24, 2025
From
Omeros Corporation
Via
Business Wire
Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)
December 01, 2025
From
Omeros Corporation
Via
Business Wire
Omeros Corporation Reports Third Quarter 2025 Financial Results
November 13, 2025
From
Omeros Corporation
Via
Business Wire
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025
November 11, 2025
From
Omeros Corporation
Via
Business Wire
Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group
October 16, 2025
From
Omeros Corporation
Via
Business Wire
The Terrific Ten Undercard: OMER, VERI, SNYR, MYSE, RDZN – Stocks Under $5 (Complete List Inside)
October 15, 2025
Via
AB Newswire
Topics
Artificial Intelligence
Cannabis
Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program
September 02, 2025
From
Omeros Corporation
Via
Business Wire
Omeros Corporation Reports Second Quarter 2025 Financial Results
August 14, 2025
From
Omeros Corporation
Via
Business Wire
Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025
August 11, 2025
From
Omeros Corporation
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
